Today before the opening bell, VistaGen Therapeutics announced its
reception of a Notice of Allowance from the Canadian Intellectual Property
Office. The Notice of Allowance enables further expansion of VistaGen
Therapeutics’ intellectual property portfolio, which consists of pluripotent
stem cell culture systems that produce human cells of the endoderm lineage,
including liver, lung, pancreas, parathyroid and thyroid cells.
The notice pertains to Canadian Patent Application No. 2,487,058, which
is exclusively licensed to VistaGen Therapeutics by the Icahn School of
Medicine at Mt. Sinai in New York and entitled “Mesoderm and Definitive
Endoderm Cell Populations”. This new development builds on VistaGen
Therapeutics’ recent reception of another Notice of Allowance for Canadian
Patent Application 2,684,022, both of which strengthen the company’s
intellectual property portfolio relating to a number of pluripotent stem cell
projects VistaGen Therapeutics has been considering pursuing in Canada.
These include: projects that involve liver safety and liver
toxicity-based drug rescue; customized drug discovery assays for therapies to
treat liver disease and diabetes; and exploratory nonclinical studies for
potential regenerative medicine applications involving beta islet cells and
other cells of the endoderm lineage.
A biotechnology company, VistaGen Therapeutics is focused on using
pluripotent stem cell technology for applications in drug rescue, drug
discovery, and regenerative medicine.
For more information, visit: www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
